SJ - yes , there are few things they talking about , but no
SJ - yes , there are few things they talking about , but no one is 100% sure that this or that is a reason for good efficacy and no serious side effects.
When recently I spoke with Dr NP , he said that FDA like Leronlimab very much , but still saying that we cant be sure if serious side effects will not appear , there is no information we can have in medicine to tell us that 100%
Just observation of patients....
Yes , with time , more often we can say , because of this or that , this probably happened.
But FDA still saying we not sure , so we want 100 patients on 700 mg as a safety for our combo...
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
8x8, Inc. Reports Strong Earnings Amid Growth Initiatives 8x8, Inc. (NASDAQ: EGHT), the prominent cloud communications provider, has experienced a notable uptick of 2% in its share value during after-hours trading following the release of their latest quarterly earnings. The company reported second quarter results that exceeded market expectations, providing a boost in...
Continue Reading
Investors Encouraged to Join Indivior PLC Securities Fraud Lawsuit The Schall Law Firm, a well-known litigation firm dedicated to protecting shareholders' rights, is reaching out to investors about an important class action lawsuit against Indivior PLC (NASDAQ: INDV). This case concerns potential breaches of the Securities Exchange Act of 1934 and Rule 10b-5 as...
Continue Reading
McDermott Strengthens Leadership with New Board Appointments McDermott International, Ltd has made a significant strategic move by announcing the addition of two accomplished professionals, Michael Martino and Farhad Nanji, to its Board of Directors. This change is aimed at bolstering the company’s leadership as it navigates the complex landscapes of the energy...
Continue Reading
United Therapeutics Reaches New Heights in Stock Value United Therapeutics Corporation (NASDAQ: UTHR) has achieved a remarkable milestone by reaching an all-time high of $366.23. This significant increase signifies a robust period of growth for the biotech company, which has seen its stock jump by an impressive 54.22% over the past year. The surge is largely attributed to...
Continue Reading
DoorDash Reaches New Stock Heights DoorDash (NASDAQ: DASH) has experienced a remarkable surge, with its stock recently hitting a 52-week high of $181.78. This leap signifies not only a thriving business model but also a considerable increase in investor confidence in the food delivery service. With a market cap of $75.3 billion, DoorDash has shown impressive growth with a...
Continue Reading
